MediWound Ltd. (NASDAQ:MDWD) Given Consensus Rating of “Hold” by Brokerages

MediWound Ltd. (NASDAQ:MDWD) has earned an average rating of “Hold” from the five research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $31.6667.

A number of equities analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target (up from $31.00) on shares of MediWound in a research report on Friday, November 21st. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a report on Thursday, January 22nd. Wall Street Zen lowered shares of MediWound from a “hold” rating to a “strong sell” rating in a research note on Saturday. Finally, Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th.

MediWound Stock Performance

Shares of NASDAQ:MDWD opened at $17.03 on Monday. The company has a market capitalization of $218.15 million, a PE ratio of -8.11 and a beta of 0.13. The stock has a fifty day moving average of $17.70 and a 200-day moving average of $17.87. MediWound has a one year low of $14.14 and a one year high of $22.50.

MediWound (NASDAQ:MDWD) last issued its earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09. The business had revenue of $1.87 million for the quarter, compared to analysts’ expectations of $2.09 million. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%. As a group, research analysts forecast that MediWound will post -2.66 EPS for the current fiscal year.

Key Headlines Impacting MediWound

Here are the key news stories impacting MediWound this week:

• Positive Sentiment: 2026–2027 revenue guidance raised/outlined above street expectations — the company issued a 2026 revenue target of $24M–$26M (vs. consensus ~$22.6M) and 2027 guidance of $32M–$35M (vs. consensus ~$25.8M), suggesting material top‑line growth ahead if execution stays on track. MediWound outlines $24M–$26M 2026 revenue target while expanding EscharEx clinical programs
• Positive Sentiment: Clinical and manufacturing progress: EscharEx Phase III (VALUE) is advancing as planned, NexoBrid manufacturing capacity has been expanded and is operational, and management expects regulatory approvals in 2026 — these operational milestones de‑risk near‑term commercialization upside. The company also finished the year with roughly $54M in cash. MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Company filed its Form 20‑F for fiscal 2025 (routine disclosure). This is standard compliance and provides more detail for investors but is not a catalyst by itself. MediWound Files Annual Report on Form 20-F
• Neutral Sentiment: Earnings call transcript and details are available for investors who want management color on 2026 assumptions and the EscharEx program; use this to judge credibility of guidance and timing of approvals. MediWound (MDWD) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 revenue missed expectations — reported quarterly revenue of $1.87M vs. analysts’ ~$2.09M estimate, highlighting a small current revenue base and near‑term sensitivity to sales execution. MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Still unprofitable with wide negative margins — Q4 GAAP loss of $0.56/sh (a smaller loss than expected), but the company reported negative net margin and return on equity, underscoring continued cash burn risk until commercial scale or regulatory approvals materialize. That combination helps explain downward pressure on the stock today. MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

Hedge Funds Weigh In On MediWound

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in MediWound by 4.4% during the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 481 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 723 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 999 shares in the last quarter. Finally, Quarry LP purchased a new position in shares of MediWound during the fourth quarter valued at $26,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.